
Sandra E. Dillahunt
Examiner (ID: 10005)
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1674, 1646 |
| Total Applications | 492 |
| Issued Applications | 240 |
| Pending Applications | 18 |
| Abandoned Applications | 239 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16791750
[patent_doc_number] => 20210121567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
[patent_app_type] => utility
[patent_app_number] => 17/137201
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17137201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/137201 | Protein formulations and methods of making same | Dec 28, 2020 | Issued |
Array
(
[id] => 17266430
[patent_doc_number] => 11191834
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => Protein formulations and methods of making same
[patent_app_type] => utility
[patent_app_number] => 17/137246
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 36
[patent_no_of_words] => 60602
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17137246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/137246 | Protein formulations and methods of making same | Dec 28, 2020 | Issued |
Array
(
[id] => 19225449
[patent_doc_number] => 12005079
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => Biologically relevant orthogonal cytokine/receptor pairs
[patent_app_type] => utility
[patent_app_number] => 16/953000
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 53
[patent_no_of_words] => 16134
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953000
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/953000 | Biologically relevant orthogonal cytokine/receptor pairs | Nov 18, 2020 | Issued |
Array
(
[id] => 16688350
[patent_doc_number] => 20210070826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/952861
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 166511
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952861
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/952861 | Multi-chain chimeric polypeptides and uses thereof | Nov 18, 2020 | Issued |
Array
(
[id] => 17213176
[patent_doc_number] => 20210346512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET
[patent_app_type] => utility
[patent_app_number] => 16/951023
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33441
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951023
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/951023 | LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET | Nov 17, 2020 | Abandoned |
Array
(
[id] => 16658661
[patent_doc_number] => 20210055298
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
[patent_app_type] => utility
[patent_app_number] => 17/085566
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085566
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/085566 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | Oct 29, 2020 | Issued |
Array
(
[id] => 16807894
[patent_doc_number] => 20210130447
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/084686
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8366
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084686
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/084686 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY | Oct 29, 2020 | Abandoned |
Array
(
[id] => 18637374
[patent_doc_number] => 11761967
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => Methods and compositions for diagnosis and prognosis of renal injury and renal failure
[patent_app_type] => utility
[patent_app_number] => 17/085351
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104245
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085351
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/085351 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | Oct 29, 2020 | Issued |
Array
(
[id] => 16570714
[patent_doc_number] => 20210009720
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => HUMAN INTERFERON-BETA VARIANT CONJUGATED IMMUNOCYTOKINE AND METHOD FOR PREPARING SAME
[patent_app_type] => utility
[patent_app_number] => 17/023207
[patent_app_country] => US
[patent_app_date] => 2020-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17023207
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/023207 | HUMAN INTERFERON-BETA VARIANT CONJUGATED IMMUNOCYTOKINE AND METHOD FOR PREPARING SAME | Sep 15, 2020 | Abandoned |
Array
(
[id] => 16539330
[patent_doc_number] => 20200405743
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/018822
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17018822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/018822 | S-antigen transport inhibiting oligonucleotide polymers and methods | Sep 10, 2020 | Issued |
Array
(
[id] => 16688351
[patent_doc_number] => 20210070827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/016003
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 134347
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016003
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/016003 | Il-2 conjugates and methods of use to treat autoimmune diseases | Sep 8, 2020 | Issued |
Array
(
[id] => 18716537
[patent_doc_number] => 11793860
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Vault complexes for cytokine delivery
[patent_app_type] => utility
[patent_app_number] => 16/991780
[patent_app_country] => US
[patent_app_date] => 2020-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 19
[patent_no_of_words] => 19536
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991780
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/991780 | Vault complexes for cytokine delivery | Aug 11, 2020 | Issued |
Array
(
[id] => 16657464
[patent_doc_number] => 20210054100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/930595
[patent_app_country] => US
[patent_app_date] => 2020-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16930595
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/930595 | Stabilized formulations containing anti-PCSK9 antibodies | Jul 15, 2020 | Issued |
Array
(
[id] => 18620450
[patent_doc_number] => 11753478
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Anti-CD115 antibodies
[patent_app_type] => utility
[patent_app_number] => 16/902940
[patent_app_country] => US
[patent_app_date] => 2020-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 17
[patent_no_of_words] => 16235
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902940
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/902940 | Anti-CD115 antibodies | Jun 15, 2020 | Issued |
Array
(
[id] => 16341733
[patent_doc_number] => 20200306383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/902256
[patent_app_country] => US
[patent_app_date] => 2020-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902256
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/902256 | Delivery constructs for transcytosis and related methods | Jun 14, 2020 | Issued |
Array
(
[id] => 16267372
[patent_doc_number] => 20200268859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => DIPEPTIDYLPEPTIDASE 4 INHIBITION ENHANCES LYMPHOCYTE TRAFFICKING, IMPROVING BOTH NATURALLY OCCURRING TUMOR IMMUNITY AND IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 15/930166
[patent_app_country] => US
[patent_app_date] => 2020-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930166
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/930166 | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy | May 11, 2020 | Issued |
Array
(
[id] => 16239616
[patent_doc_number] => 20200256850
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => METHOD FOR EVALUATING EFFECT OF CYTOKINE ON METABOLIC ACTIVITY OF CYTOCHROME P450, AND DRUG SCREENING METHOD
[patent_app_type] => utility
[patent_app_number] => 16/859305
[patent_app_country] => US
[patent_app_date] => 2020-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859305
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/859305 | METHOD FOR EVALUATING EFFECT OF CYTOKINE ON METABOLIC ACTIVITY OF CYTOCHROME P450, AND DRUG SCREENING METHOD | Apr 26, 2020 | Abandoned |
Array
(
[id] => 16222790
[patent_doc_number] => 20200247906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => PCSK9 ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 16/857929
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33049
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857929
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/857929 | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | Apr 23, 2020 | Issued |
Array
(
[id] => 16343618
[patent_doc_number] => 20200308268
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 16/828736
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828736
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828736 | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | Mar 23, 2020 | Issued |
Array
(
[id] => 16343974
[patent_doc_number] => 20200308624
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => Phosphate and tensin homolog (PTEN) for the detection of autoimmune diseases or conditions
[patent_app_type] => utility
[patent_app_number] => 16/826335
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4913
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826335
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/826335 | Phosphate and tensin homolog (PTEN) for the detection of autoimmune diseases or conditions | Mar 22, 2020 | Abandoned |